Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
View original at nasdaq.comLo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
Initial safety, tolerability, pharmacokinetic, and immune data for MDX2001 are expected in the first half of 2027.
60% confidenceKiniksa raised its full-year 2026 net product revenue guidance for Arcalyst to $980 million to $995 million.
60% confidenceProMIS expects to report topline 12-month results from the PRECISE-AD trial in the first quarter of 2027.
60% confidenceOPKO expects full-year 2026 total revenue of $560 million to $580 million.
60% confidencePrelude expects an IND application submission for PRT13722 by mid-2026 and a Phase 1 study initiation in ER-positive breast cancer in the second half of 2026.
60% confidenceEnrollment for the MDX2301 Phase 1 trial is expected to be completed in Q3 2026, with initial data anticipated in late 2026 or early 2027.
60% confidenceOPKO forecasts Q3 2026 revenue of $131 million to $142 million.
60% confidenceMapLight plans to engage the FDA at an End-of-Phase 2 meeting to discuss the path forward for ML-007C-MA in schizophrenia, including the design of a Phase 3 trial.
60% confidenceThe VISTA trial is designed to enroll approximately 300 participants, with topline results expected in the second half of 2027.
60% confidence